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tially more expensive than on-demand treatment, is associated with greater clin-
ical efficacy and improved long-term outcomes, which may lead to cost savings
over a patient’s lifetime. CONCLUSIONS: Hemophilia A is associated with consid-
erable humanistic and economic burden. Substantial unmet needs remain among
hemophilia A patients with regard to the safety, convenience and global access to
FVIII therapy.
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OBJECTIVES: To assess the functional form of the minimally important difference
(MID)METHODS: Subjects were shown a base body weight, y1, and a current body
weight after a treatment, y2. If a subject endorsed y2 as an important difference
over y1, we denoted a pair (y2, y1). An MID is the y1 and y2 difference when the
probability of discriminating y2 fromy1was greater than 0.5. The standard formula
of this discrimination probability is given by Fechner’s Law: P(y2, y1)  F(U(y2) -
U(y1)) where F is an increasing function and U is a MID function. When the proba-
bility of discrimination is constant over proportional changes in weight (i.e., We-
ber’s Law: P(y2, y1)  P(y2, y1)), the utility function for health states is a log
function. To assess the functional form of U, we tested a hypothesis of P(y2, y1) 
P(y2, y1) 0.5. An on-line survey was conducted with three base weights: 29, 36,
and 43 lb overweight. One-way repeated measure analysis of variance (Wilk’s test)
and one-way within subjects analysis were used. RESULTS: A total of 131 subjects
participated. ThemeanMID values were 9.391 (SD 4.001), 11.195 (SD 5.236), and
13.073 (SD  6.491) for 29, 36, and 43 lb overweight, respectively. The normalized
mean MID values were 0.323 (SD  0.138), 0.311 (SD 0.145), and 0.304 (SD  0.151)
for 29, 36, and 43 lb overweight, respectively. The results of Wilk’s test was not
statistically significant (p  0.2807) Moreover, one-way within subjects resulted in
no effect of the different body weights on theMIDs at the significance level 0.01.
CONCLUSIONS: The normalized mean MIDs from three different body weights
were not statistically different. Within the limited range studied MIDs fit a log
utility model. Thus, MIDs may be problematic as a prescriptive policy tool.
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OBJECTIVES: The NIH roadmap project “Patient-Reported OutcomesMeasurement
Information System” (PROMIS) provides a basis for measuring symptoms - includ-
ing fatigue; associated with chronic diseases. However, information on use of PRO-
MIS with Fibromyalgia (FM) patients is limited. This study sought to evaluate the
factor structure of the 95-item PROMIS Fatigue item bank among individuals with
FM. It is unknown whether the conceptual structure of fatigue experience (inten-
sity, frequency, and duration) and impact (physical and mental) will be supported
in individuals with FM.METHODS: An internet-based survey was conducted with
individuals with FM. Participants had to be 18 years and diagnosed with FM by a
physician. Respondents were randomized into one of three cohorts, each of which
completed one-third of the 95-items from the entire PROMIS v1.0 Fatigue ItemBank
(www.nihpromis.org). Items were balanced between cohorts. Item factor analysis
was performed using both a polychoric correlation matrix with Mplus and a full-
information approach using ORDFAC. Comparisons were made using the Akaike
Information Criteria (AIC) and Bayesian Information Criterion (BIC). Models chosen
based on BIC produced interpretable factors for assessment of the PROMAX rotated
factor loadings. RESULTS: 1,207 respondents completed the survey. Mean age of
the respondents was 52.1 years. Mean time since FM diagnosis was 8.7 years. All
groups produced factor structures that included 3 factors. The first consisted
mainly of Fatigue Experience items. The second consisted mainly of items related
to Mental Impact and the third consisted of General Impact items. An additional
factor related to Social Impact was identified in Group B only. CONCLUSIONS: For
individuals with FM, the PROMIS Fatigue item bank appears to contain a factor
structure that is consistent with the original PROMIS conceptual model. Subscales
from the PROMIS Fatigue item bank can likely be used to separate Fatigue Experi-
ence from General and Mental impacts of Fatigue.
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OBJECTIVES: The NIH roadmap project “Patient-Reported OutcomesMeasurement
Information System” (PROMIS) provides a basis for measuring symptoms - includ-
ing fatigue; associatedwith chronic diseases. However, information on use of PROMIS
with Fibromyalgia (FM) patients is limited. This study sought to re-estimate the
Item Response Theory (IRT) item parameter estimates for each of the 95-items
included in the PROMIS Fatigue item bank using responses from individuals with
FM. It is unknown whether the parameter estimates differ among a sample of FM
patients from that of the broader population used in the initial PROMIS item
calibrations.METHODS:An internet-based survey was conducted with individuals
with FM. Participants had to be 18 years and diagnosed with FM by a physician.
Respondents were randomized into one of three cohorts, each of which completed
one-third of the 95-items from the entire PROMIS v1.0 Fatigue ItemBank (www.nih-
promis.org). IRT model fitting of Samejima’s Graded Response Model (GRM) was
conducted using MULTILOG7 to determine item parameter estimates and com-
pared with standard PROMIS parameter estimates. RESULTS: A total of 1,207 re-
spondents completed the survey. IRT item parameter estimates (slope and item
characteristic curve thresholds) and item information functions were obtained for
all 95-items. Mean score across all items for the FM sample was 3.68 compared to
the PROMISmeanof 2.12.Maximum information functionwas2 for 22/95 items in
the FM sample, compared to only 2/95 items in the PROMIS sample, indicating
differences in both discriminate ability as well as the difficulty of items for a FM
specific population. CONCLUSIONS:Disease specific item level calibrations of PRO-
MIS items can be estimated. Using the same GRMmethodology as PROMISwewere
able to calculate revised item parameter estimates and information functions.
These estimates can be used to construct improved efficient short-forms or for
application in computer adaptive testing.
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OBJECTIVES: To evaluate the reliability and validity of the Lupus Impact Tracker
(LIT), a patient-based assessment of systemic lupus erythematosus (SLE) disease
impact.METHODS: Reliability and validity of scale scores using the 10 selected LIT
items were evaluated using two datasets (cross-sectional, n253 and longitudinal,
n307) which collected information on quality of life (SF-36), disease activity (SLE-
DAI total score, revised SELENA flare index) and patients’ overall general health
rating (GHR) from LupusPRO©. Internal consistency reliability (ICR) was estimated
in both studies using Cronbach’s alpha. In the longitudinal dataset, reliability was
also evaluated by computing the intra-class correlation between LIT scale scores at
baseline and follow-up. Convergent validity was evaluated by correlating LIT scale
score with SF-36, disease activity and GHR. Construct validity was examined by
known-groups validity (comparing mean scale scores across groups known to dif-
fer on conceptually related criterion measures). Analysis of variance was con-
ducted to compare LIT scale scores across patients stratified by each criterion
measure. Responsiveness was studied using known-groups validity. Specifically,
the magnitude and direction of mean score changes on the LIT scale against
changes in GHR (0-100 scale) were evaluated. RESULTS: The 10 LIT items (concen-
tration, medication side effects, fulfilling family responsibilities, woke up feeling
worn out, pain and aching in body, limited activities due to pain/fatigue, anxiety,
depression, self conscious about appearance, ability to plan activities) showed
good ICR (0.89) and test-retest reliability (0.87). LIT items correlated moderately
(r0.5) with SF-36 domains and summary measures and the GHR. Mean scale
scores differed significantly (p0.05) in the hypothesized direction across groups
stratified by disease activity and GHR. CONCLUSIONS: The Lupus Impact Tracker,
a 10-item PRO, is reliable and valid and offers a practical way of assessing the
impact of lupus on a patient’s life.
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OBJECTIVES: To derive a short form questionnaire from the LupusPRO©, for use in
daily practice to assess the impact of SLE. METHODS: LupusPRO is a 44-item vali-
dated quality of life instrument. To identify the subset of items that would fit a
unidimensional structure, one-factor confirmatory factor analysis (CFA) and item-
to-factor loadings and goodness of fit statistics (Confirmatory Fit Index [CFI], Tucker-
Lewis Index [TLI]) were conducted. Backward stepwise regression methods were
used to eliminate items that showed the weakest relationship to clinical criterion
measures of disease activity (SLEDAI total score, revised SELENA flare index) and
patients’ overall general health ratings (from LupusPRO). Four focus groups were
conducted: patients were asked to rate each item of LupusPRO using a 4-point
importance scale and to identify the “top 15” most important items. RESULTS:
Based on CFA, 21 items fit a unidimensional structure. Both goodness of fit statis-
tics (CFI,TLI) exceeded the recommended threshold of 0.9. All items showed high
factor loadings ranging from 0.76 to 0.91. Backward stepwise regression analyses
resulted in 12 items most highly related to patient and clinical criterion measures.
Of focus group participants, 80% rated the top 15 items as “moderately” or “very”
important (importance ratings  2.3). In total 7 items were selected across the 3
approaches (CFA, backward regression, focus groups). Another 14 were selected
based on results from at least 2 approaches. Items measuring symptoms and pro-
creation were excluded: symptom items did not fit with the intent of the tool;
procreation items would not apply to all patients. Finally, changes in the item
selection based on clinical consensus were made, without losing psychometric
properties. CONCLUSIONS: Using quantitative and qualitative methods, 10 items
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were selected for inclusion in the Lupus Impact Tracker, a PRO intended for clinical
practice use to monitor the impact of SLE on patients’ lives and well being.
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OBJECTIVES: A daily assessment of the speed of action and effectiveness of treat-
ment of a combination of paracetamol and codeine in patients suffering from
intense pain, which has progressed since less than 7 days.METHODS: Amulticen-
tre longitudinal observational prospective study carried out inmetropolitan France
using data collected by general practitionerswho agreed to participate. RESULTS:A
total of 574 patients treated by a paracetamol-codeine combination (600mg/50mg
and 400mg/20mg) were included. The severity of pain measured at inclusion using
a visual numeric scalewas 71.28. The severity of painmeasured after half a day of
treatment was 5.611.87 and 5.28  1.86 at the end of the first 24 hours of treat-
ment. A significant improvement in pain was observed from the first half-day
(p0.001). The severity of pain on the 2nd, 4th and 7th evenings was respectively
4.081.85; 2.761.76 and 1.79 1.69 On D1, 69.7% declared treatment to be effec-
tive, 61.04%were satisfiedwith their treatment and 79.26%did not observe any side
effects to the treatment. On D7, 96.15% (D3, 91.3% ) declared treatment to be effec-
tive, 87.10%were satisfiedwith their treatment and 88.96%did not observe any side
effects to the treatment. 8 out of 10 patients did not complain about side effects
related to the treatment. CONCLUSIONS: A reduction in pain within the first 12
hours showed the pertinence of treatment using a paracetamol-codeine combina-
tion. This pertinencewas confirmed by two-thirds patients who declared the treat-
ment to be effective from the 1st day, and 91% of them declared this on the 3rd day
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OBJECTIVES: The diabetic peripheral neuropathy (DPN) is the most common
chronic complication of diabetes. Neuropathic pain tends to be severe, chronic, and
has a hugely negative impact on the physical and emotional functioning, and over-
all well-being of the patient. This study was performed to evaluate the scope of
pain and quality of life among patients with painful diabetic peripheral
neuropathy.METHODS: A cross-sectional, observational study was carried out on
type 2 diabetic patients from 40 medical centers throughout Korea. The standard-
ized questionnaires such as Michigan Neuropathy Screening Instrument (MNSI),
Brief Pain Inventory-short form (BPI-sf), MOS 6-items Sleep Scale and EuroQoL
(EQ-5D) were used to diagnosis and estimate the quality of life in people with DPN.
A patient with DPN was defined as the patients who showed positive patients
medical records or neuropathic symptoms (MNSI2) and positive response on the
basic neurological examination (Monofilament test). RESULTS: Among 4,000 dia-
betic patients, 33.5% had DPN. Of those 1,338 DPN patients, 874 (65.3%) took pain
medications or had 1 worst pain scores (BPI-sf, 0-10 scales). Patients who took
pain medications or had 1 worst pain scores were 6310.6 years old (57.9% fe-
male), had diabetes for 138.0 years and DPN for 4.03.3 years. Average andWorst
Pain score were 2.92.3 and 4.93.1. Pain interference index were higher in pa-
tientswho took painmedications or had1worst pain scores (2.42.6 and 0.20.8,
respectively, P0.0001). Pain substantially interfered with general activity, mood,
walking, normal work, relationships, sleep, and enjoyment of life. These patients
reported greater sleep problems compared with DPN patients without pain. The
mean EQ-5D utility score was 0.60.2. CONCLUSIONS: This study found that pain
associated with diabetic neuropathy is a significant medical issue that has a sub-
stantial impact on the quality of life of many people with this condition.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patientswith hereditary coagulopathies inKazakhstan.METHODS: Postal and tele-
phone health survey. Questionnaires were distributed in May - August 2009. The
questionnaire contained questions on clotting factor level, number of bleeding,
number of injections of clotting factors, ways of receiving medications, number of
ambulance calls and hospitalizations, and the way of administration ofmedicines.
The patients’ education level and employment data was collected. Analysis was
performed with 2 and Student’s criteria. RESULTS: 626 completed questionnaires
were received by September, 2009. Hemophilia A was reported by 486 responders
(77.6%). 426 patients (68%) were adults. Mean age was 25.4 years. 60 patients with
hemophilia A and B (11.6%) had a level of coagulation factors lower then 1%, i.e.
they had a severe form of disease. The presence of antibodies was detected in 68
patients (11%). 87.8% of patients experienced bleeding in the last month. The me-
dian of a number of bleeding among all bled patients was 2. 84.4% of patients used
clotting factors in the last month. The median number of injections of clotting
factor VIII in patients with hemophilia A was 2 (standard frequency is 12). 7.2% of
patients called for an ambulance in a lastmonth (medium frequency of calls in last
month – 2). 7.4% of patients were hospitalized during last month (medium fre-
quency of hospitalization – 2). 564 (90.2%) of patients perform the injections of
clotting factor themselves. 12.8% of patients reported use of prophylaxis scheme of
treatment hemophilia, 70.6% of patients reported use of “on demand” scheme.
CONCLUSIONS: Results of survey showed very low rate of treatment of hemophilia
with proper prophylactic scheme (less than 13%of patients). The rate of ambulance
calls and hospitalizations is comparatively low. Themajority of patients introduce
the factors themselves.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patients with hereditary coagulopathies in Ukraine.METHODS: Postal health sur-
vey. Questionnaires were distributed in May - August 2009. The questionnaire
contained questions on clotting factor level, number of bleeding, injections of clot-
ting factors, ways of receiving medications, number of ambulance calls and hospi-
talizations, and the way of administration of medicines. Analysis of experimental
data was performed with such statistical parameters as 2 and Student’s criteria.
RESULTS: 154 completed questionnaires were received by September, 2009. Hemo-
philia Awas reported by 103 responders (67%). 126 (81.8%) patientswere adults. The
detection of a level of coagulation factors during last year was done in 50 (40.4%)
patients with hemophilia A and B. 24 (19.4%) patients with hemophilia A and B had
a level of coagulation factors lower then 1%, i.e. they had a severe form of disease.
The presence of antibodies was detected in 27 patients (17.5%). 80.6% of patients
experienced bleeding during the last month (median - 4). 51.4% of patients with
hemophilia A used clotting factor VIII during last month. The median number of
injections of clotting factor VIII in patients with hemophilia A was 4 (standard
frequency is 12). 36.4% of patients called for an ambulance during last month
(medium frequency – 1). 49.3% of patients were hospitalized during last month
(medium frequency – 1). Only 23 (15%) of patients performed the injections of
clotting factor themselves. Only 1.3% of patients reported use of prophylaxis
scheme of treatment hemophilia, 85.7% of patients reported use of “on demand”
scheme. CONCLUSIONS: Results of survey showed very low rate of treatment of
hemophilia with proper prophylactic scheme (about than 1.3% of patients). The
rate of ambulance calls and hospitalizations is extremely high. The majority of
patients introduce the factors in hospitals.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patientswith hereditary coagulopathies inKazakhstan.METHODS: Postal and tele-
phone health survey. Questionnaires were distributed in May - August 2009. The
questionnaire contained questions on clotting factor level and presence of anti-
bodies to it, number of bleeding in last month, number of injections of clotting
factors per month, names of used medications, ways of receiving medications,
number of ambulance calls and hospitalizations, and the way of administration of
medicines (self-administration of administration at a ambulatory/hospital). The
patients’ education level and employment datawas collected. Health-related qual-
ity of life was assessed with self-administrated validated version of Russian ver-
sion of Euroqol-5D questionnaire. Comparisonwasmadewith health-related qual-
ity of life of Russian patients data (P.Vorobeyv et. al., 2008, data of 1003 patientswas
used in analyses). RESULTS: 626 completed questionnaires were received by Sep-
tember, 2009. Health-related quality of life was assessed for patients older than 11
years (n 514). More than half of patients reported problems within each of EQ-5D
dimensions of health. Thus 63.9% of patients reported of problems (moderate and
severe) with mobility (63.9% of Russian patients, p0.05); 65.2% of patients in-
formed of difficulties with self-care (35.5% of Russian patients, p0.05); 70.1% of
patients had difficultieswith usual activity (61.9% of Russian patients, p0.05); 74%
of patients reported of presence of pain or discomfort (78.4% of Russian patients,
p0.05); 27.3% of patients had an anxiety or depression (54.2% of Russian patients,
p0.05). The average value of quality of life evaluated with visual-analog scale
(VAS) was 0.53 (SD 0.18), median - 50. CONCLUSIONS: Results of the study shown
high rate of problemswithmobility, usual activity and high rate of pain/discomfort
and low rate of problem with anxiety/depression.
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OBJECTIVES: To assess epidemiology of anemia cased by chronic renal failure in
patients on dialysis and patient’s quality of life. METHODS: Health survey of pa-
tients in dialysis departments of 23 regions. About 1400 questionnaires were dis-
tributed in May - June 2010. The form contained following questions: personal
information (name, age, patients’ education and employment), medical data (di-
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